Table 3 Association between the distribution of TAB2 rs237028 genotypes and patient’s characteristics
Characteristics | Genotype | OR (95% CI) a | ||||
|---|---|---|---|---|---|---|
AA | AG | GG | Dominant (AA vs. AG/GG) | Recessive (AA/AG vs. GG) | Over-dominant (AA/GG vs. AG) | |
Age | ||||||
<43 | 32 (53.3%) | 22 (36.7%) | 6 (10.0%) | 0.97 1.01 (0.49–2.10) | 0.98 1.02 (0.28–3.63) | 0.98 1.01 (0.48–2.12) |
≥43 | 38 (52.8%) | 27 (37.5%) | 7 (9.7%) | |||
FIGO Stage | ||||||
Stage I | 34 (54.0%) | 23 (36.5%) | 6 (9.5%) | 0.99 1.00 (0.43–2.32) | 0.61 0.65 (0.12–3.56) | 0.80 1.12 (0.47–2.67) |
Stage II-III | 36 (52.2%) | 26 (37.7%) | 7 (10.1%) | |||
Pathological type | ||||||
Squamous | 60 (53.1%) | 40 (35.4%) | 13 (11.5%) | 0.79 0.86 (0.30–2.52) | 0.01 0.00 (0.00-NA) | 0.37 1.63 (0.56–4.71) |
Others | 10 (52.6%) | 9 (47.4%) | 0 (0.0%) | |||
Tumor differentiation | ||||||
Low | 55 (56.7%) | 33 (34.0%) | 9 (9.3%) | 0.05 2.35 (0.97–5.66) | 0.15 3.03 (0.71–12.97) | 0.25 1.65 (0.70–3.89) |
Mod-High | 15 (42.9%) | 16 (45.7%) | 4 (11.4%) | |||
Lymph node involvement | ||||||
Positive | 11 (40.7%) | 9 (33.3%) | 7 (25.9%) | 0.74 0.83 (0.28–2.46) | 0.0006 0.01 (0.00-0.31) | 0.12 2.46 (0.75–8.04) |
Negative | 59 (56.2%) | 40 (38.1%) | 6 (5.7%) | |||
Myometrial invasion | ||||||
>1/2 | 38 (50.7%) | 31 (41.3%) | 6 (8.0%) | 0.56 1.28 (0.56–2.93) | 0.006 17.97 (1.50-216.02) | 0.49 0.75 (0.33–1.71) |
≤1/2 | 32 (56.1%) | 18 (31.6%) | 7 (12.3%) | |||
Peritumoral intravascular cancer emboli | ||||||
Positive | 22 (43.1%) | 21 (41.2%) | 8 (15.7%) | 0.06 0.45 (0.19–1.04) | 0.12 0.29 (0.06–1.38) | 0.28 0.63 (0.27–1.48) |
Negative | 48 (59.3%) | 28 (34.6%) | 5 (6.2%) | |||
Involve others | ||||||
Positive | 26 (55.3%) | 18 (38.3%) | 3 (6.4%) | 0.46 | 0.17 | 1.00 |
Negative | 44 (51.8%) | 31 (36.5%) | 10 (11.8%) | 1.36 (0.60–3.05) | 2.96 (0.58–15.03) | 1.00 (0.44–2.27) |